

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-22. (Canceled)

23. (Currently Amended) A method for detecting prostate cancer in a patient comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein said oligonucleotides primers are specific for nucleotide residues 1341-2694 of SEQ ID NO:110 and full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110; and

(c) detecting in the sample an expressed polynucleotide sequence that amplifies in the presence of the oligonucleotide primers thereby detecting prostate cancer, wherein the biological sample is selected from the group consisting of blood and semen; and wherein the oligonucleotide primers consist of at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, or full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110.

24. (Canceled)

25.-34. (Canceled)

35. (Currently Amended) A method for detecting the presence of an expressed polynucleotide sequence of SEQ ID NO: 110 in a biological sample, the method comprising:

(a) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein the oligonucleotide primers are specific for nucleotide

residues 1341-2694 of SEQ ID NO:110 and full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110; and

(b) detecting in the sample an expressed polynucleotide sequence that amplifies in the presence of the oligonucleotide primers, wherein the biological sample is selected from the group consisting of blood and semen, and wherein the oligonucleotide primers consist of at least about 10 contiguous nucleotides of nucleotide residues 1341-2694 of SEQ ID NO:110, or full length complements of nucleotide residues 1341-2694 of SEQ ID NO:110.

36. (Canceled)

37.-46. (Canceled)